ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

patritumab deruxtecan

Also written as “HER3-DXd”, “Patritumab deruxtecan” and “Patritumab Deruxtecan”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Esophageal Neoplasms · Melanoma · Neoplasms, led by 2 companies.

Drug pagePatritumab deruxtecan: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 2, 202517 company-led studies, 15 open or runningCo-development: Daiichi Sankyo and Merck, Oct 2023Next primary completion: May 9, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only99 open or runningphase 3since Jul 2, 2025Nov 14, 2019May 9, 2028phase 2 · NCT06445972
Daiichi Sankyo86 open or runningphase 3since Apr 15, 2022Nov 28, 2016Nov 19, 2030phase 2 · NCT06172478
  • Named in Merck’s own pipeline as patritumab deruxtecan (MK-1022), phase 3, as of Nov 2, 2026 (source).

Also a collaborator on its studies: AstraZeneca.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Daiichi Sankyo only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 28, 2016First study: phase 2 study in Breast NeoplasmsFirst studyNCT02980341 · 182 enrolled · United States, Japan
  2. Aug 22, 2017Phase 1 study in Carcinoma, Non-Small-Cell LungNCT03260491 · 312 enrolled · United States, Japan, Netherlands and more
  3. Jun 9, 2019Named patritumab deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 121
  4. Jul 13, 2020Phase 2 study in Colorectal NeoplasmsNCT04479436 · 40 enrolled · United States, Belgium, France and more
  5. Oct 29, 2020Phase 2 study in Non-Small Cell Lung Cancer MetastaticNCT04619004 · 277 enrolled · United States, Australia, Austria and more
  6. Dec 15, 2020Phase 1 study in Carcinoma, Non-Small-Cell LungNCT04676477 · 246 enrolled · United States, Japan, South Korea and more
  7. Apr 15, 2022Phase 3 study in Nonsquamous Non-small Cell Lung CancerNCT05338970 · 586 enrolled · United States, Australia, Austria and more
  8. Oct 19, 2023Merck develops it with Daiichi SankyoCo-developmentWorldwide except Japan, where Daiichi Sankyo keeps the rights · announced · Merck
  9. Dec 7, 2023Phase 2 study in MelanomaNCT06172478 · 890 planned · United States, Australia, Belgium and more
  10. Jul 8, 2026Phase 2 study in Breast NeoplasmsNCT07701941 · 220 planned · United States, Belgium, France and more
  11. Nov 17, 2026Primary completion moved from 2027-09-01 to 2030-11-19Date moved laterphase 2 · +39 months · NCT06172478

Ahead

  1. Nov 19, 2030Primary completion: phase 2 study in MelanomaNCT06172478
  2. Jan 1, 2031Primary completion: phase 2 study in Breast NeoplasmsNCT07701941

TargetBeta

“An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),linked to the topoisomerase I inhibitor DX 8951, a semisynthetic, water-soluble derivative of camptothecin, with potential antineoplastic activit…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),”NCIt, by rule
“Receptor tyrosine-protein kinase erbB-3 binding agent”ChEMBL 37, by rule

Other programs on ERBB3

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
beruzatatug pelitecanruleMediLink Therapeutics (Suzhou)phase 39
ruzaltatug rezetecanJiangsu HengRui Medicinephase 38
JSKN016ruleAlphamab Oncologyphase 35
SYS6023ruleCSPC Pharmaceutical Groupphase 22
Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002rulexadcera-biopharmaceutical-suzhou-co-ltdphase 21
Anti-HER3/Exatecan Antibody-drug Conjugate ENV-501rulehummingbird-biosciencephase 21
Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418ruleavenzo-therapeutics-incphase 21
KHN922ruleChengdu Kanghong Pharmaceutical Groupphase 21
CS5007ruleCStone Pharmaceuticalsphase 11
JSKN016HCruleAlphamab Oncologyphase 11

Studies

All 8 Daiichi Sankyo leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07701941Breast Neoplasms · United States, Belgium, France and more2RecruitingJan 1, 2031220
NCT06172478Melanoma · United States, Australia, Belgium and more2RecruitingNov 19, 2030890
NCT05338970Nonsquamous Non-small Cell Lung Cancer · United States, Australia, Austria and more3Active, not recruitingMay 31, 2024586
NCT04676477Carcinoma, Non-Small-Cell Lung · United States, Japan, South Korea and more1Active, not recruitingJan 31, 2025246
NCT04619004Non-Small Cell Lung Cancer Metastatic · United States, Australia, Austria and more2Active, not recruitingNov 21, 2022277
NCT04479436Colorectal Neoplasms · United States, Belgium, France and more2TerminatedFeb 3, 202240
NCT03260491Carcinoma, Non-Small-Cell Lung · United States, Japan, Netherlands and more1Active, not recruitingDec 1, 2025312
NCT02980341Breast Neoplasms · United States, Japan2CompletedAug 16, 2021182

How it is read

Names in the registry

  • “HER3-DXd”, 8 entries
  • “Patritumab deruxtecan”, 5 entries
  • “Patritumab Deruxtecan”, 5 entries
  • “Patritumab Deruxtecan (Fixed dose)”, 1 entry
  • “Patritumab Deruxtecan (Up-Titration)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.